A study published in Science Advances reveals a novel strategy that allows tumors to evade the body’s immune response critical for their elimination.
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001 | Psychedelic Invest
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid
September 12, 2023